TScan Therapeutics (TCRX) Other Non-Current Assets (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly Other Non-Current Assets of $5.0 million for Q1 2026, little changed year-over-year from $5.0 million in Q1 2025, and little changed quarter-over-quarter from $5.0 million in Q4 2025.
TScan Therapeutics (TCRX) Other Non-Current Assets (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Other Non-Current Assets for 7 consecutive years, with $5.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets changed 0.0% year-over-year to $5.0 million; the TTM figure through Mar 2026 stood at $5.0 million (changed 0.0% YoY), while the FY2025 annual figure was $5.0 million, up 184.88% from the prior year.
- Other Non-Current Assets was little changed at $5.0 million in Q1 2026 per TCRX's latest filing, from $5.0 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $5.0 million in Q2 2022 and bottomed at $1.8 million in Q4 2024.
- Historically, Other Non-Current Assets has averaged $4.6 million across 5 years, with a median of $5.0 million in 2022.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets surged 746.55% — and 2024, when it tumbled 64.9%.
- TScan Therapeutics' Other Non-Current Assets stood at $5.0 million in 2022, then retreated by 0.12% to $5.0 million in 2023, then sank by 64.9% to $1.8 million in 2024, then jumped by 184.88% to $5.0 million in 2025, then changed by 0.0% to $5.0 million in 2026.
- Business Quant data shows TCRX's Other Non-Current Assets at $5.0 million in Q1 2026, $5.0 million in Q4 2025, and $5.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | 5.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.03 Mn |
| Mar 31, 2026 | 5.03 Mn |
| Dec 31, 2025 | 5.03 Mn |
| Sep 30, 2025 | 5.03 Mn |
| Jun 30, 2025 | 1.78 Mn |
| Mar 31, 2025 | 5.03 Mn |
| Dec 31, 2024 | 1.77 Mn |
| Sep 30, 2024 | 5.03 Mn |
| Jun 30, 2024 | 5.03 Mn |
| Mar 31, 2024 | 5.03 Mn |
| Dec 31, 2023 | 5.03 Mn |
| Sep 30, 2023 | 5.03 Mn |
| Jun 30, 2023 | 5.03 Mn |
| Mar 31, 2023 | 5.03 Mn |
| Dec 31, 2022 | 5.04 Mn |
| Sep 30, 2022 | 5.04 Mn |
| Jun 30, 2022 | 5.04 Mn |
| Mar 31, 2022 | 5.03 Mn |
| Dec 31, 2021 | 5.03 Mn |
| Sep 30, 2021 | 595,000.00 |